Chemotherapy-induced peripheral neurotoxicity: A critical analysis

CA Cancer Journal for Clinicians

Volumn 63, Issue 6, 2013, Pages 419-437

  Park, Susanna B ^a,b   Goldstein, David ^c   Krishnan, Arun V ^c   Lin, Cindy S Y ^b   Friedlander, Michael L ^a   Cassidy, James ^d   Koltzenburg, Martin ^a   Kiernan, Matthew C ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

chemotherapy; neuropathy; neurotoxicity; survivorship

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BORTEZOMIB; CANNABINOID; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GLUTAMINE; GLUTATHIONE; LENALIDOMIDE; LEVACECARNINE; MINOCYCLINE; NALOXONE; OXALIPLATIN; OXYCODONE; PACLITAXEL; PREGABALIN; PYRIDOXINE; RILUZOLE; TAXANE DERIVATIVE; THALIDOMIDE; THIOCTIC ACID; UNINDEXED DRUG; VENLAFAXINE; VINCRISTINE;

ACTION POTENTIAL; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVERSE OUTCOME; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ASSESSMENT; CRYOTHERAPY; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; GENETIC POLYMORPHISM; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MULTIPLE MYELOMA; NERVE CONDUCTION; NEUROPATHY SENSORY SUBSCALE; NEUROPROTECTION; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OTOTOXICITY; OUTCOME ASSESSMENT; OVARY CANCER; PARANEOPLASTIC NEUROPATHY; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PRIORITY JOURNAL; RATING SCALE; RAYNAUD PHENOMENON; REVIEW; SENSORY NEUROPATHY; SINGLE DRUG DOSE; SPINAL GANGLION; TOTAL NEUROPATHY SCORE; TRIPLE NEGATIVE BREAST CANCER;

CHEMOTHERAPY; NEUROPATHY; NEUROTOXICITY; SURVIVORSHIP;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; QUALITY OF LIFE; RISK FACTORS; SURVIVORS;

EID: 84887564905     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21204     Document Type: Review

References (224)

1. Boyle P, Levin B, eds. World Cancer Report. Lyon, France: International Agency for Research on Cancer; 2008.
2. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute; 2013, based on the November 2012 SEER data submission. seer.cancer.gov/csr/1975-2010/.
3. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C,. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer. 2008; 44: 1507-1515.
4. Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. Am Fam Physician. 2004; 69: 548-556. (Pubitemid 38176273)
5. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F,. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006; 33: 15-49. (Pubitemid 43214485)
6. Allen DT, Kiernan JA,. Permeation of proteins from the blood into peripheral nerves and ganglia. Neuroscience. 1994; 59: 755-764. (Pubitemid 24131527)
7. Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 1992; 10: 795-803.
8. Krarup-Hansen A, Rietz B, Krarup C, et al. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin. Neuropathol Appl Neurobiol. 1999; 25: 29-40. (Pubitemid 29121692)
9. Ta LE, Espeset L, Podratz J, Windebank AJ,. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006; 27: 992-1002. (Pubitemid 44838955)
10. Dzagnidze A, Katsarava Z, Makhalova J, et al. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci. 2007; 27: 9451-9457. (Pubitemid 47358200)
11. Peters CM, Jimenez-Andrade JM, Kuskowski MA, et al. An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. Brain Res. 2007; 1168: 46-59. (Pubitemid 47320623)
12. Topp KS, Tanner KD, Levine JD,. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol. 2000; 424: 563-576. (Pubitemid 30643051)
13. Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy: a ganglionopathy? Neurology. 2003; 60: 877-878. (Pubitemid 36297380)
14. Casafont I, Berciano MT, Lafarga M,. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox Res. 2010; 17: 167-178.
15. Theiss C, Meller K,. Taxol impairs anterograde axonal transport of microinjected horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell Tissue Res. 2000; 299: 213-224. (Pubitemid 30103139)
16. Lapointe NE, Morfini G, Brady ST, et al. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013; 37: 231-239.
17. Poruchynsky MS, Sackett DL, Robey RW, et al. Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: a possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition. Cell Cycle. 2008; 7: 940-949. (Pubitemid 351573790)
18. Flatters SJL, Bennett GJ,. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006; 122: 245-257. (Pubitemid 43729476)
19. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol. 2007; 204: 317-325. (Pubitemid 46330280)
20. Kirchmair R, Tietz AB, Panagiotou E, et al. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide-induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther. 2007; 15: 69-75. (Pubitemid 46043651)
21. Melli G, Jack C, Lambrinos GL, et al. Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration. Neurobiol Dis. 2006; 24: 525-530. (Pubitemid 44716681)
22. Silva A, Wang Q, Wang M, et al. Evidence for direct axonal toxicity in vincristine neuropathy. J Peripher Nerv Syst. 2006; 11: 211-216. (Pubitemid 44286071)
23. Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features. Acta Neurol Scand. 2004; 109: 188-193. (Pubitemid 38270874)
24. Adelsberger H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na channel kinetics on rat sensory neurons. Eur J Pharmacol. 2000; 406: 25-32.
25. Webster RG, Brain KL, Wilson RH, et al. Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol. 2005; 146: 1027-1039. (Pubitemid 41722176)
26. Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A. 2012; 109: 6704-6709.
27. Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011; 18: 19-e3.
28. Giometto B, Grisold W, Vitaliani R, et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol. 2010; 67: 330-335.
29. Camdessanché JP, Antoine JC, Honnorat J, et al. Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain. 2002; 125: 166-175. (Pubitemid 34084046)
30. Antoine JC, Camdessanché JP,. Paraneoplastic disorders of the peripheral nervous system. Presse Med. 2013; 42 (6 pt 2): e235-e244.
31. Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2009; 80: 412-416.
32. Richardson PG, Laubach JP, Schlossman RL, et al. Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Cancer Netw. 2010; 8 (1 suppl 1): S4-S12.
33. Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006; 24: 4507-4514. (Pubitemid 46630990)
34. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009; 27: 3518-3525.
35. Malhotra P, Choudhary PP, Lal V, Varma N, Suri V, Varma S,. Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis. Leuk Lymphoma. 2011; 52: 2135-2138.
36. Lanzani F, Mattavelli L, Frigeni B, et al. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2008; 13: 267-274.
37. Ramchandren S, Lewis RA,. An update on monoclonal gammopathy and neuropathy. Curr Neurol Neurosci Rep. 2012; 12: 102-110.
38. Dispenzieri A,. POEMS syndrome: update on diagnosis, risk-stratification, and management. Am J Hematol. 2012; 87: 804-814.
39. Rajabally YA,. Neuropathy and paraproteins: review of a complex association. Eur J Neurol. 2011; 18: 1291-1298.
40. Kuwabara S, Dispenzieri A, Arimura K, Misawa S, Nakaseko C,. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev. 2012; 6: CD006828.
41. Viala K, Behin A, Maisonobe T, et al. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry. 2008; 79: 778-782. (Pubitemid 351914723)
42. Klein CJ, Moon JS, Mauermann ML, et al. The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS. Can J Neurol Sci. 2011; 38: 289-295.
43. Giometto B, Vitaliani R, Lindeck-Pozza E, et al. Treatment for paraneoplastic neuropathies. Cochrane Database Syst Rev. 2012; 12: CD007625.
44. Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010; 46: 479-494.
45. Griffith KA, Merkies ISJ, Hill EE, Cornblath DR,. Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst. 2010; 15: 314-325.
46. Fromme EK, Eilers KM, Mori M, Hsieh Y-C, Beer TM,. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004; 22: 3485-3490. (Pubitemid 41103654)
47. Basch E, Iasonos A, McDonough T, et al. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006; 7: 903-909. (Pubitemid 44615944)
48. Stubblefield MD, McNeely ML, Alfano CM, Mayer DK,. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy. Cancer. 2012; 118: 2250-2260.
49. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13: 176-181. (Pubitemid 36962641)
50. Postma TJ, Heimans JJ, Muller MJ, et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol. 1998; 9: 739-744. (Pubitemid 28394160)
51. Cavaletti G, Cornblath DR, Merkies ISJ, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol. 2013; 24: 454-462.
52. Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology. 1999; 53: 1660-1664. (Pubitemid 29530336)
53. Chaudhry V, Cornblath DR, Corse A, et al. Thalidomide-induced neuropathy. Neurology. 2002; 59: 1872-1875. (Pubitemid 36076557)
54. Cavaletti G, Bogliun G, Marzorati L, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale. Neurology. 2003; 61: 1297-1300. (Pubitemid 37377562)
55. Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst. 2007; 12: 210-215. (Pubitemid 47404378)
56. Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2006; 11: 135-141. (Pubitemid 43894080)
57. Frigeni B, Piatti M, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst. 2011; 16: 228-236.
58. Smith EM, Cohen JA, Pett MA, Beck SL,. The reliability and validity of a modified total neuropathy score-reduced and neuropathic pain severity items when used to measure chemotherapy-induced peripheral neuropathy in patients receiving taxanes and platinums. Cancer Nurs. 2010; 33: 173-183.
59. Sasane M, Tencer T, French A, et al. Patient-reported outcomes in chemotherapy-induced peripheral neuropathy: a review. J Support Oncol. 2010; 8: e15-e21.
60. Cirillo M, Venturini M, Ciccarelli L, et al. Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire. Ann Oncol. 2009; 20: 1929-1935.
61. Morton RF, Sloan JA, Grothey A, et al. A comparison of simple single-item measures and the common toxicity criteria in detecting the onset of oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. J Clin Oncol. 2005; 23 (suppl 16): 8087.
62. Postma TJ, Aaronson NK, Heimans JJ, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005; 41: 1135-1139. (Pubitemid 40725571)
63. Calhoun EA, Welshman EE, Chang C-H, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003; 13: 741-748. (Pubitemid 38235217)
64. Hershman D, Weimer L, Wang A, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat. 2011; 125: 767-774.
65. Huang HQ, Brady MF, Cella D, Fleming G,. Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer. 2007; 17: 387-393. (Pubitemid 46426765)
66. Driessen CML, de Kleine-Bolt KME, Vingerhoets AJJM, Mols F, Vreugdenhil G,. Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer. 2012; 20: 877-881.
67. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA,. Measuring the side effects of taxane therapy in oncology. Cancer. 2003; 98: 822-831.
68. Kopec JA, Land SR, Cecchini RS, et al. Validation of a self-reported neurotoxicity scale in patients with operable colon cancer receiving oxaliplatin. J Support Oncol. 2006; 4: W1-W8.
69. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006; 24: 3113-3120. (Pubitemid 46638949)
70. Cella D, Huang H, Homesley HD, et al. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184. Gynecol Oncol. 2010; 119: 538-542.
71. Moore DH, Donnelly J, McGuire WP, et al. Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity. J Clin Oncol. 2003; 21: 4207-4213. (Pubitemid 46606190)
72. Wolf SL, Barton DL, Qin R, et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer. 2012; 20: 625-632.
73. Lavoie Smith EM, Barton DL, Qin R, et al. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire [published online ahead of print March 30, 2013 ]. Qual Life Res.
74. Shimozuma K, Ohashi Y, Takeuchi A, et al. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer. 2009; 17: 1483-1491.
75. Shimozuma K, Ohashi Y, Takeuchi A, et al. Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer. 2012; 20: 3356-3364.
76. Binda D, Vanhoutte EK, Cavaletti G, et al. CI-PeriNomS study group. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). Eur J Cancer. 2013; 49: 2910-2918.
77. Basch E, Bennett A, Pietanza MC,. Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst. 2011; 103: 1808-1810.
78. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012; 30: 4249-4255.
79. Stubblefield MD, Burstein HJ, Burton AW, et al. NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009; 7 (suppl 5): S1-S26.
80. Inoue N, Ishida H, Sano M, et al. Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. Int J Clin Oncol. 2012; 17: 341-347.
81. Oldenburg J, Fossa S, Dahl A,. Scale for chemotherapy-induced long-term neurotoxicity (SCIN): psychometrics, validation, and findings in a large sample of testicular cancer survivors. Qual Life Res. 2006; 15: 791-800. (Pubitemid 43800751)
82. LoMonaco M, Milone M, Batocchi AP, et al. Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol. 1992; 239: 199-204.
83. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR,. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994; 35: 304-311. (Pubitemid 24089653)
84. Pietrangeli A, Leandri M, Terzoli E, Jandolo B, Garufi C,. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol. 2006; 56: 13-16. (Pubitemid 44359537)
85. Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK,. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004; 29: 387-392. (Pubitemid 38269758)
86. Kiernan MC, Burke D, Andersen KV, Bostock H,. Multiple measures of axonal excitability: a new approach in clinical testing. Muscle Nerve. 2000; 23: 399-409. (Pubitemid 30126986)
87. Park SB, Lin CS-Y, Krishnan AV, et al. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain. 2009; 132: 2712-2723.
88. Park SB, Goldstein D, Lin CS-Y, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol. 2009; 27: 1243-1249.
89. Forsyth P, Balmaceda C, Peterson K, et al. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997; 35: 47-53. (Pubitemid 27361845)
90. Attal N, Bouhassira D, Gautron M, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: a prospective quantified sensory assessment study. Pain. 2009; 144: 245-252.
91. Pestronk A, Florence J, Levine T, et al. Sensory exam with a quantitative tuning fork: rapid, sensitive and predictive of SNAP amplitude. Neurology. 2004; 62: 461-464. (Pubitemid 38200861)
92. Rolke R, Baron R, Maier C, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006; 123: 231-243.
93. Cavaletti G, Alberti P, Marmiroli P,. Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics. Lancet Oncol. 2011; 12: 1151-1161.
94. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA,. Glutathione S-transferase P1 polymorphism predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res. 2006; 12: 3050-3056. (Pubitemid 43837350)
95. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX4 chemotherapy. J Clin Oncol. 2007; 25: 1247-1254. (Pubitemid 46640571)
96. McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer. J Clin Oncol. 2010; 28: 3227-3233.
97. Goekkurt E, Al-Batran SE, Hartmann JT, et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin. J Clin Oncol. 2009; 27: 2863-2873.
98. Kweekel DM, Gelderblom H, Antonini NF, et al. Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer. 2009; 45: 572-578.
99. Boige V, Mendiboure J, Pignon JP, et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU, FOLFOX and FOLFIRI: FFCD 2000-05. J Clin Oncol. 2010; 28: 2556-2564.
100. Oldenburg J, Kraggerud SM, Brydoy M, Cvancarova M, Lothe RA, Fossa SD,. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med. 2007; 5: 70.
101. Leskelä S, Jara C, Leandro-García LJ, et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics. 2011; 11: 121-129.
102. Marsh S, Paul J, King CR, Gifford C, McLeod HL, Brown R,. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer. J Clin Oncol. 2007; 25: 4528-4535. (Pubitemid 350035308)
103. Bergmann TK, Green H, Brasch-Andersen C, et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol. 2011; 67: 693-700.
104. Dennison JB, Jones DR, Renbarger JL, Hall SD,. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J Pharmacol Exp Ther. 2007; 321: 553-563. (Pubitemid 46628594)
105. Egbelakin A, Ferguson MJ, MacGill EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011; 56: 361-367.
106. Won HH, Lee J, Park JO, et al. Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer. 2012; 118: 2828-2836.
107. Johnson DC, Corthals SL, Walker BA, et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011; 29: 797-804.
108. Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol. 2010; 11: 1057-1065.
109. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP,. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol. 2008; 66: 218-228.
110. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC,. Neurotoxicity of taxol. J Natl Cancer Inst Monogr. 1993;(15): 107-115.
111. Reeves BN, Dakhil SR, Sloan JA, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012; 118: 5171-5178.
112. Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer. J Clin Oncol. 2004; 22: 2061-2068. (Pubitemid 41095138)
113. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol. 1996; 14: 1858-1867. (Pubitemid 26185461)
114. Moulder SL, Holmes FA, Tolcher AW, et al. A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer. Cancer. 2010; 116: 814-821.
115. Smith RE, Brown AM, Mamounas EP, et al. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26. J Clin Oncol. 1999; 17: 3403-3411. (Pubitemid 29517907)
116. Mielke S, Mross K, Gerds TA, et al. Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs. 2003; 14: 785-792. (Pubitemid 38339782)
117. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009; 27: 3611-3619.
118. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005; 23: 5983-5992.
119. Rivera E, Mejia JA, Arun BK, et al. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer. 2008; 112: 1455-1461. (Pubitemid 351459423)
120. Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004; 15: 1358-1365. (Pubitemid 39295024)
121. Mauri D, Kamposioras K, Tsali L, et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a meta-analysis. Cancer Treat Rev. 2010; 36: 69-74.
122. Schröder CP, de Munck L, Westermann AM, et al. Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel. Eur J Cancer. 2011; 47: 1355-1362.
123. Perez EA, Suman VJ, Rowland KM, et al. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2005; 6: 425-432. (Pubitemid 43078898)
124. Budd GT, Barlow WE, Moore, HCF, et al. Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer [abstract]. J Clin Oncol. 2013; 31. Abstract CRA1008.
125. Huang TC, Campbell TC,. Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumors: a meta-analysis. Cancer Treat Rev. 2012; 38: 613-617.
126. Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008; 358: 1663-1671. (Pubitemid 351549913)
127. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008; 26: 1642-1649.
128. Fountzilas G, Dafni U, Dimopoulos M, et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat. 2009; 115: 87-99.
129. Zhang Z, Mei L, Feng SS,. Paclitaxel drug delivery systems. Expert Opin Drug Deliv. 2013; 10: 325-340.
130. Pace A, Nistico C, Cuppone F, et al. Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clin Breast Cancer. 2007; 7: 550-554. (Pubitemid 46725247)
131. Pignata S, De Placido S, Biamonte R, et al. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer. 2006; 6: 5.
132. Osmani K, Vignes S, Aissi M, et al. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol. 2012; 259: 1936-1943.
133. Tanabe Y, Hashimoto K, Shimizu C,. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol. 2013; 18: 132-138.
134. Hile ES, Fitzgerald GK, Studenski SA,. Persistent mobility disability after neurotoxic chemotherapy. Phys Ther. 2010; 90: 1649-1657.
135. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350: 2343-2351. (Pubitemid 38702845)
136. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol. 2009; 27: 3109-3116.
137. Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002; 20: 1767-1774. (Pubitemid 34273265)
138. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000; 18: 2938-2947. (Pubitemid 30644117)
139. Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013; 119: 438-444.
140. Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 1990; 25: 299-303. (Pubitemid 20014976)
141. Petrioli R, Pascucci A, Francini E, et al. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin. Cancer Chemother Pharmacol. 2008; 61: 105-111. (Pubitemid 47512632)
142. Grothey A,. Reintroduction of oxaliplatin: a viable approach to the
143. Adams RA, Meade AM, Seymour MT, et al. MRC COIN Trial Investigators. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011; 12: 642-653.
144. Argyriou AA, Velasco R, Briani C, et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol. 2012; 23: 3116-3122.
145. Madi A, Fisher D, Wilson RH, et al. Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. Br J Cancer. 2012; 107: 1037-1043.
146. Rothenberg ML, Cox JV, Butts C, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol. 2008; 19: 1720-1726.
147. Díaz-Rubio E, Tabernero J, Gõmez-España A, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer. J Clin Oncol. 2007; 25: 4224-4230.
148. Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D,. Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer. 2012; 20: 2959-2967.
149. Land SR, Kopec JA, Cecchini RS, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007; 25: 2205-2211. (Pubitemid 46954644)
150. Kidwell KM, Yothers G, Ganz PA, et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer. Cancer. 2012; 118: 5614-5622.
151. Mols F, Beijers T, Lemmens V, et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013; 31: 2699-2707.
152. Park SB, Lin CS, Krishnan AV, et al. Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist. 2011; 16: 708-716.
153. Burakgazi AZ, Messersmith W, Vaidya D, et al. Longitudinal assessment of oxaliplatin-induced neuropathy. Neurology. 2011; 77: 980-986.
154. Brouwers EE, Huitema AD, Boogerd W, Beijnen JH, Schellens JH,. Persistent neuropathy after treatment with cisplatin and oxaliplatin. Acta Oncol. 2009; 48: 832-841.
155. Cavaletti G, Marzorati L, Bogliun G, et al. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer. 1992; 69: 203-207.
156. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rorth M, Krarup C,. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain. 2007; 130: 1076-1088. (Pubitemid 47355585)
157. van den Bent MJ, van Putten WLJ, Hilkens PHE, de Wit R, van der Burg MEL,. Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. Eur J Cancer. 2002; 38: 387-391. (Pubitemid 34121966)
158. von Schlippe M, Fowler CJ, Harland SJ,. Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br J Cancer. 2001; 85: 823-826. (Pubitemid 33010547)
159. Albers P, Siener R, Krege S, et al. German Testicular Cancer Study Group. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008; 26: 2966-2972.
160. de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001; 19: 1629-1640. (Pubitemid 32230862)
161. Grimison PS, Stockler MR, Thomson DB, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst. 2010; 102: 1253-1262.
162. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol. 1991; 9: 1163-1172.
163. Siegal T, Haim N,. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer. 1990; 66: 1117-1123. (Pubitemid 20310648)
164. Brydøy M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst. 2009; 101: 1682-1695.
165. Brouwers EE, Huitema AD, Beijnen JH, Schellens JH,. Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol. 2008; 8: 7.
166. Sprauten M, Darrah TH, Peterson DR, et al. Impact of long-term serum platinum concentrations on neuro- and ototoxicity in cisplatin-treated survivors of testicular cancer. J Clin Oncol. 2012; 30: 300-307.
167. Strumberg D, Brügge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol. 2002; 13: 229-236. (Pubitemid 34704974)
168. Verstappen CCP, Koeppen S, Heimans JJ, et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology. 2005; 64: 1076-1077. (Pubitemid 40388469)
169. Postma TJ, Benard BA, Huijgens PC, Ossenkoppele GJ, Heimans JJ,. Long-term effects of vincristine on the peripheral nervous system. J Neurooncol. 1993; 15: 23-27. (Pubitemid 23049695)
170. Haim N, Epelbaum R, Ben-Shahar M, et al. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer. 1994; 73: 2515-2519. (Pubitemid 24155527)
171. Hirvonen HE, Salmi TT, Heinonen E, Antila KJ, Välimäki IA,. Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy. Cancer. 1989; 64: 801-805. (Pubitemid 19188815)
172. Hancock BW, Naysmith A,. Vincristine-induced autonomic neuropathy. Br Med J. 1975; 3: 207.
173. González Pérez P, Serrano-Pozo A, Franco-Macías E, Montes-Latorre E, Gomez-Aranda F, Campos T,. Vincristine-induced acute neurotoxicity versus Guillain-Barré syndrome: a diagnostic dilemma. Eur J Neurol. 2007; 14: 826-828. (Pubitemid 47012181)
174. Wanschitz J, Dichtl W, Budka H, Loscher WN, Boesch S,. Acute motor and sensory axonal neuropathy in Burkitt-like lymphoma. Muscle Nerve. 2006; 34: 494-498. (Pubitemid 44506721)
175. Bahl A, Chakrabarty B, Gulati S, Raju KN, Raja A, Bakhshi S,. Acute onset flaccid quadriparesis in pediatric non-Hodgkin lymphoma: vincristine induced or Guillain-Barré syndrome? Pediatr Blood Cancer. 2010; 55: 1234-1235.
176. Aral YZ, Gursel T, Ozturk G, Serdaroglu A,. Guillain-Barré syndrome in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2001; 18: 343-346. (Pubitemid 32625515)
177. Re D, Schwenk A, Hegener P, Bamborschke S, Diehl V, Tesch H,. Guillain-Barré syndrome in a patient with non-Hodgkin's lymphoma. Ann Oncol. 2000; 11: 217-220. (Pubitemid 30148738)
178. Brigo F, Balter R, Marradi P, et al. Vincristine-related neuropathy versus acute inflammatory demyelinating polyradiculoneuropathy in children with acute lymphoblastic leukemia. J Child Neurol. 2012; 27: 867-874.
179. Yuki N, Hartung HP,. Guillain-Barré syndrome. N Engl J Med. 2012; 366: 2294-2304.
180. Naumann R, Mohm J, Reuner U, Kroschinsky F, Rautenstrauss B, Ehninger G,. Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity. Br J Haematol. 2001; 115: 323-325. (Pubitemid 34203496)
181. Moriyama B, Henning SA, Leung J, et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses. 2012; 55: 290-297.
182. Rodriguez MA, Pytlik R, Kozak T, et al. Marqibo Investigators. Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer. 2009; 115: 3475-3482.
183. Moser E, Noordijk E, Carde P, et al. Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma. 2005; 6: 122-130.
184. Ramchandren S, Leonard M, Mody RJ, et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst. 2009; 14: 184-189.
185. Kim BJ, Park HR, Roh H, et al. Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Quality Life Res. 2010; 19: 1097-1103.
186. Yakoub-Agha I, Mary JY, Hulin C, et al. Intergroupe Francophone du Myelome (IFM). Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myelome. Eur J Haematol. 2012; 88: 249-259.
187. Kropff M, Giongco-Baylon H, Hillengass J, et al. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012; 97: 784-791.
188. Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity. Neurology. 2004; 62: 2291-2293.
189. Zara G, Ermani M, Rondinone R, Arienti S, Doria A,. Thalidomide and sensory neurotoxicity: a neurophysiological study. J Neurol Neurosurg Psychiatry. 2008; 79: 1258-1261.
190. Steurer M, Spizzo G, Mitterer M, Gastl G,. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. Onkologie. 2004; 27: 150-154. (Pubitemid 38621605)
191. Feyler S, Rawstron A, Jackson G, Snowden JA, Cocks K, Johnson RJ,. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Br J Haematol. 2007; 139: 429-433. (Pubitemid 47512183)
192. Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term (> 1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol. 2005; 74: 212-216. (Pubitemid 40278490)
193. Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma. Blood. 2010; 115: 1343-1350.
194. Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006; 354: 1021-1030. (Pubitemid 43357806)
195. Stratogianni A, Tosch M, Schlemmer H, et al. Bortezomib-induced severe autonomic neuropathy. Clin Auton Res. 2012; 22: 199-202.
196. El-Cheikh J, Stoppa AM, Bouabdallah R, et al. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma. Clin Lymphoma Myeloma. 2008; 8: 146-152.
197. Ravaglia S, Corso A, Piccolo G, et al. Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol. 2008; 119: 2507-2512.
198. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009; 144: 895-903.
199. Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010; 115: 3416-3417.
200. Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan- prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol. 2011; 86: 23-31.
201. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010; 116: 4745-4753.
202. Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010; 11: 1086-1095.
203. Boyette-Davis JA, Cata JP, Zhang H, et al. Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. J Pain. 2011; 12: 1017-1024.
204. Albers J, Chaudhry V, Cavaletti G, Donehower R,. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2007;(1): CD005228.
205. Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002; 20: 3478-3483.
206. Wang WS, Lin JK, Lin TC, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist. 2007; 12: 312-319.
207. Stubblefield MD, Vahdat LT, Balmaceda CM, Troxel AB, Hesdorffer CS, Gooch CL,. Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study. Clin Oncol (R Coll Radiol). 2005; 17: 271-276. (Pubitemid 40716452)
208. Lin PC, Lee MY, Wang WS, et al. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer. 2006; 14: 484-487.
209. Pace A, Giannarelli D, Galie E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology. 2010; 74: 762-766.
210. Argyriou AA, Chroni E, Koutras A, et al. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer. 2006; 14: 1134-1140. (Pubitemid 44898796)
211. Kottschade LA, Sloan JA, Mazurczak MA, et al. The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy. Support Care Cancer. 2011; 19: 1769-1777.
212. Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer. J Clin Oncol. 2011; 29: 421-427.
213. Wen F, Zhou Y, Wang W, et al. Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis. Ann Oncol. 2013; 24: 171-178.
214. Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT). J Clin Oncol. 2013; 31 (suppl). Abstract 3501.
215. Gamelin L, Boisdron-Celle M, Morel A, et al. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol. 2008; 26: 1188-1119.
216. Durand JP, Deplanque G, Montheil V, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity. Ann Oncol. 2012; 23: 200-205.
217. Argyriou AA, Chroni E, Polychronopoulos P, et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006; 67: 2253-2255. (Pubitemid 46035491)
218. Smith EM, Pang H, Cirrincione C, et al. Alliance for Clinical Trials in Oncology. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy; a randomized clinical trial. JAMA. 2013; 309: 1359-1367.
219. Kautio AL, Haanpaa M, Leminen A, Kalso E, Kautiainen H, Saarto T,. Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms. Anticancer Res. 2009; 29: 2601-2606.
220. Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy. Cancer. 2007; 110: 2110-2118.
221. Rao RD, Flynn PJ, Sloan JA, et al. Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy. Cancer. 2008; 112: 2802-2808.
222. Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C,. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs. 2007; 11: 901-913.
223. Gewandter JS, Fan L, Magnuson A, et al. Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. Support Care Cancer. 2013; 21: 2059-2066.
224. Tofthagen C, Visovsky C, Berry DL,. Strength and balance training for adults with peripheral neuropathy and high risk of fall: current evidence and implications for future research. Oncol Nurs Forum. 2012; 39: E416-E424.